Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Brilliant news from MGC today re the first UK patient to receive CannEpil for epilepsy treatment. As many have posted on here for quite some time we know that there is a massive unmet need for epilepsy treatment in the UK and worldwide. The big news contained in the RNS today is confirmation that CannEpil is being prescribed via Named Patient Request for the first time. In summary, MGC is making significant progress in the epilepsy space. This is a very big market with latest research highlighting that nine people in every 1,000 people have epilepsy each year in the UK. This means that an estimated 633,000 people are living with epilepsy in the UK. Globally the figure is huge with approx 50 million people having epilepsy, making it one of the most common neurological diseases. This is a big day for MGC investors.
Good luck, Brighty
... Moreover, a side door for patients is now open in the UK to access these powerful, effective drugs, besmirched by suspicion and fear probably, through the NHS's Refractory Epilepsy Specialist Clinical Advisory Service. This is finally happening. This company has shown their hand and determination to succeed in very difficult circumstances. Massive Congratulations. Its snow balling time!
I feel that there is no awareness of this, nothing in uk media to push this. Just dont think ppl are aware of this groundbreaking journey that has started. Sp still bleeds out.
Under the radar for sure. The competition isnt doing as well as it could either. This stock must surely have its day. It is groundbreaking and ticks green boxes.Like most industries right now it is facing additional financial pressures, these guys dont give up though. Im certain it is just a matter of time for it to find its way into mainstream consciousness once more. Once the sales pick up, I reckon the company will push the advertising. Social media will play its part too. If these treatments really do their job, who wouldnt want to tell the world?
A friend of mine's lovely daughter died 2 years ago as a result of an epilepsy episode. She would have jumped at the chance to trial CannEpil. MGC is an emotianal hold for me